Completed EARLY_PHASE1 INTERVENTIONAL NCT00606424

An Exploratory, Open Label, Single Center Study of [F-18]HX4 (HX4)

Sponsor: Siemens Molecular Imaging

Interventions 20 mCi dose for a 50 kg individual of [F-18]HX4

Updated 6 times since 2017 Last updated: Jan 29, 2009 Started: Jan 31, 2008 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Head and Neck Cancer, this trial is completed. The trial is conducted by Siemens Molecular Imaging and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Siemens Molecular Imaging

Data source: Siemens Molecular Imaging

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States